Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has provided a detailed report on the management and usage of raised funds for the first half of 2025, ensuring compliance with regulatory requirements and transparency in financial practices [1]. Fundraising Overview - The company raised a total of RMB 394 million through its initial public offering (IPO), with a net amount of RMB 347 million after deducting issuance costs [1]. - The non-public offering raised RMB 500 million, with a net amount after costs also verified by an accounting firm [1]. Fund Management - The company has established a dedicated fund management policy to ensure the effective use of raised funds, adhering to relevant laws and regulations [1]. - Funds are stored in special accounts, and the company has signed tripartite supervision agreements with banks to ensure proper management [1][2]. Fund Usage - As of June 30, 2025, the company has utilized RMB 346.34 million from the IPO funds and RMB 498.10 million from the non-public offering funds for various projects [4][5]. - The company has not used any raised funds for temporary working capital or to replace pre-invested funds in the projects [5][6]. Project Changes - The company has made several changes to its fundraising projects, including the implementation subject and location for the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project, which is now managed by a wholly-owned subsidiary [3][12]. - The company has also adjusted the use of unspent funds from previous projects to new project investments, ensuring compliance with regulations [4][6]. Financial Performance - The company reported that the cumulative investment in the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project reached RMB 73.31 million, while the "Animal Health Products Comprehensive Production Base" project was completed with a total investment of RMB 104.16 million [8][10]. - The company has not encountered any significant issues in the usage and disclosure of raised funds, maintaining transparency and compliance with regulatory requirements [7][11].